Table 2.
Studies included in meta-analysis
| ADC name | Study first author, year | Cancer type | Study design/phase/site | ADC group sample size | Modified NOS rating |
|---|---|---|---|---|---|
| Belantamab mafadotin | Lonial, 2021 | Multiple myeloma | RCT/2/multicenter | 97 | Good |
| Brentuximab vedotin | Pro, 2012 | Systemic ALCL | Single-arm study/2/Multicenter | 58 | Fair |
| Younes, 2012 | Hodgkin lymphoma | Single-arm study/2/Multicenter | 102 | Good | |
| Horwitz, 2014 | PTCL | Single-arm study/2/Multicenter | 35 | Fair | |
| Monjanel, 2014 | Hodgkin lymphoma, ALCL | Retrospective cohort study/2/Single center | 45 | Good | |
| Duvic, 2015 | pcALCL, MF | Single-arm study/2/Single center | 54 | Good | |
| Kim, 2015 | MF, Sezary syndromeS | Single-arm study/2/Multicenter | 32 | Fair | |
| Prince, 2017 | MF, pcALCL | RCT/3/Multicenter | 64 | Good | |
| Walewski, 2018 | Hodgkin lymphoma | Single-arm study/4/Multicenter | 60 | Good | |
| Stefoni, 2020 | Hodgkin lymphoma | Single-arm study/2/Multicenter | 18 | Good | |
| Kuruvilla, 2021 | Hodgkin lymphoma | RCT/3/Multicenter | 153 | Good | |
| Song, 2021 | Hodgkin lymphoma, ALCL | Single-arm study/2/Multicenter | 39 | Fair | |
| Enfortumab vedotin | Rosenberg, 2019 | Urothelial cancer | Single-arm study/2/Multicenter | 125 | Good |
| Powles, 2021 | Urothelial cancer | RCT/3/Multicenter | 301 | Good | |
| Yu, 2021 | Urothelial cancer | Single-arm study/2/Multicenter | 89 | Good | |
| Gemtuzumab ozogamicin | Taksin, 2007 | AML | Single-arm study/2/Multicenter | 57 | Fair |
| Amadori, 2016 | AML | RCT/3/Multicenter | 118 | Good | |
| Inotuzumab ozogamicin | Kantarjian, 2013 | ALL | Single-arm study/1.5/Single center | 41 | Good |
| Kantarjian, 2019 | ALL | RCT/3/Multicenter | 164 | Good | |
| Loncastuximab tesirine | Caimi, 2021 | DLBCL | Single-arm study/2/Multicenter | 145 | Good |
| Moxetumomab pasudoxtox | Kreitman, 2021 | Hairy cell leukemia | Single-arm study/2/Multicenter | 80 | Good |
|
Sacituzumab govitecan |
Bardia, 2019 | Breast cancer | Single-arm study/1.5/Multicenter | 108 | Good |
| Bardia, 2021 | Breast cancer | RCT/3/Multicenter | 258 | Good | |
| Tagawa, 2021 | Urothelial cancer | Non-randomized multicohort study/2/Multicenter | 113 | Good | |
| Tisotumab vedotin | Hong, 2020 | Cervical cancer | Single-arm study/1.5/Multicenter | 55 | Fair |
| Coleman, 2021 | Cervical cancer | Single-arm study/2/Multicenter | 101 | Good | |
| Trastuzumab deruxtecan | Modi, 2020 | Breast cancer | Single-arm study/2/Multicenter | 184 | Good |
| Shitara, 2020 | Gastric cancer | RCT/2/Multicenter | 125 | Good | |
| Cortés, 2022 | Breast cancer | RCT/3/Multicenter | 261 | Good | |
| Trastuzumab emtansine | Burris, 2011 | Breast cancer | Single-arm study/2/Multicenter | 112 | Good |
| Krop, 2012 | Breast cancer | Single-arm study/2/Multicenter | 110 | Good | |
| Verma, 2012 | Breast cancer | RCT/3/Multicenter | 495 | Good | |
| Yardley, 2015 | Breast cancer | Single-arm study/4/Multicenter | 215 | Good | |
| Kashiwaba, 2016 | Breast cancer | Single-arm study/2/Multicenter | 73 | Good | |
| Krop, 2017 | Breast cancer | RCT/3/Multicenter | 403 | Good | |
| Watanabe, 2017 | Breast cancer | Single-arm study/2/Multicenter | 232 | Fair | |
| Montemurro, 2019 | Breast cancer | Single-arm study/3b/Multicenter | 2002 | Good | |
| Von Minckwitz, 2019 | Breast cancer | RCT/3/Multicenter | 743 | Good | |
| Cortés, 2020 | Breast cancer | RCT/1.5/Multicenter | 80 | Fair | |
| Emens, 2020 | Breast cancer | RCT/2/Multicenter | 69 | Good | |
| Cortés, 2022 | Breast cancer | RCT/3/Multicenter | 263 | Good |
ALCL anaplastic large cell lymphoma, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, DLBCL diffuse large B-cell lymphoma, MF mycosis fungoides, NOS Newcastle–Ottawa scale, pcALCL primary cutaneous ALCL, PTCL peripheral T cell lymphoma, RCT randomized controlled trial